Working… Menu

Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00366132
Recruitment Status : Unknown
Verified August 2006 by Tissue Regeneration Technologies.
Recruitment status was:  Recruiting
First Posted : August 18, 2006
Last Update Posted : August 18, 2006
Information provided by:
Tissue Regeneration Technologies

Brief Summary:
The purpose of this clinical study is to compare the safety and effectiveness of shockwave treatment combined with standard-of-care treatment, to standard-of-care treatment alone to induce healing of a chronic plantar foot ulcer in subjects with diabetes mellitus. For the purpose of this study, the definition of plantar foot ulcer is a wound or open sore that involves the plantar(bottom) aspect of the foot, and the definition of chronic is a duration of 6 weeks or greater with a lack of response to treatment.

Condition or disease Intervention/treatment Phase
Chronic Diabetic Foot Ulcers Device: Extracorporeal Shockwaves Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: DermaGold Indicated for Use of Shockwave Treat of Diabetic Foot Ulcers in Patients With Diabetes Mellitus
Study Start Date : March 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Time to Complete Wound Healing

Secondary Outcome Measures :
  1. o A comparison of the total number of subjects with a final status of "Healed" in the active versus control group
  2. o Partial healing at 12 weeks post treatment ((size of wound compared to baseline));
  3. o Results of quantitative wound cultures (Ulcers with a quantitative wound culture with a bacterial count greater than 105 per gram of tissue will be defined as an infected ulcer);
  4. o The percentage of the wound that has healed
  5. o The number of shock wave treatments performed
  6. o Durability of wound closure (i.e., status of wound at one week following determination of "healed")

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of a single chronic plantar foot ulcer that has persisted for a minimum of 6 weeks duration
  • History of Type 2 diabetes mellitus; (track/ask if insulin dependent)
  • Capable of wound care at home;
  • The ulcer measures > 1 cm and <4 cm at any dimension
  • The ulcer is Stage 1 or 2A according to the classification system described by Lavery et al.
  • Stage 1 - superficial wounds through the epidemis or epidermis and dermis that did not penetrate to tendon, capsule or bone.
  • Stage 2A - Clean wounds that penetrated to tendon or capsule.
  • Palpable pedal pulse in the affected leg OR peripheral vascular disease evaluation demonstrating acceptable blood supply to affected foot;
  • Subjects age > 18 years;
  • The Investigator has completed a medical history and a physical examination to assure that the subject meets all study enrollment criteria;
  • The subject is willing and able to read, understand and sign the study specific informed consent form; and
  • The subject agrees to comply with study protocol requirements, including the shockwave procedure, self-care of the wound (e.g., wet to wet dressings, orthotics) and all follow up visit requirements.

Exclusion Criteria:

  • Pregnancy
  • Type I diabetes
  • Plantar foot ulcer extends to and /or involves the bone or joint;
  • Ulcers are present on both feet
  • Multiple ulcers on the foot
  • Clinical evidence of cellulitis at the ulcer site or surrounding area;
  • Ulcers that have purulent exudates or malodorous exudates on visual examination
  • Diagnosis of a chronic plantar foot ulcer that has persisted for >1 year.
  • Peripheral vascular disease per the study enrollment work-up requiring vascular surgery intervention.
  • ABI (Ankle Brachial Index) < 0.6 Ulcer debridement under anesthesia in OR required within the 2 week observation phase,
  • Lower extremity revascularization procedure (e.g. PTA, graft, etc.) within eight (8) weeks of the study screening visit.
  • Uncorrected biomechanical abnormalities that cause or contribute to the affected lower extremity ulcer; (e.g. tight Achilles tendon, hammer toe, Charcot foot etc.)
  • Surgical procedure to correct biomechanical abnormities (e.g., lengthening of the Achilles tendon. correction of hammer toe, Charcot foot correction) within eight (8) weeks of the study screening visit;
  • Deep vein thrombosis within 6 months of study screening visit;
  • Clinical evidence of lymphadema;
  • Active or previous (within 60 days prior to the study screening visit) chemotherapy;
  • Treatment of the plantar foot ulcer with growth factors, prostaglandin therapy or vasodilator therapy during the 2 week observation phase.
  • Subject on steroid therapy
  • Sickle cell anemia
  • Infection with Human Immunodeficiency Virus
  • Immunodeficiency disorders
  • Severe protein malnutrition - serum albumin < 2.0g/dl
  • Severe anemia - Hgb < 7 g/dl (males) or < 6.5 (females)
  • Recent treatment (within 60 days prior to the study screening visit) with immunosuppresants, radiation, or biologically active cellular / acellular products;
  • Current history of substance abuse.
  • Physical or mental disability or geographical concerns (residence not within reasonable travel distance) that would hamper compliance with required study visits;
  • Current participation in another clinical investigation of a medical device or a drug, or recent participation in such a study within 30 days prior to study enrollment; or
  • The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements, including the shock wave treatment procedure, standard-of-care self-care requirements, and all study-related follow up visit requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00366132

Layout table for location information
United States, District of Columbia
Georgetown University Hospital Recruiting
Washington, D.C., District of Columbia, United States, 20007
Contact: Rene Laughlin, RN    202-444-7288      
Principal Investigator: Christopher Attinger, MD         
United States, New York
Calvary Hospital Recruiting
Bronx, New York, United States, 10461
Contact: Linda Waltrous    718-518-2149      
Principal Investigator: Oscar Alvarez, Ph.D.,WCA         
United States, Ohio
Akron General Recruiting
Akron, Ohio, United States, 44307
Contact: Dawn Sues, RN    330-344-1122      
Principal Investigator: David Kay, MD         
United States, Texas
University of Texas Medical Branch Recruiting
Galveston, Texas, United States, 77555
Contact: Matthew Wagener, BS    409-747-5749      
Principal Investigator: Saul Trevino, MD         
Podiatry Group of South Texas Recruiting
San Antonio, Texas, United States, 78229
Contact: Rebecca Reyes    830-981-5150      
Principal Investigator: Richard L Childers, DPM         
Sponsors and Collaborators
Tissue Regeneration Technologies
Layout table for additonal information Identifier: NCT00366132    
Other Study ID Numbers: G050198
First Posted: August 18, 2006    Key Record Dates
Last Update Posted: August 18, 2006
Last Verified: August 2006
Keywords provided by Tissue Regeneration Technologies:
Foot Ulcers
Diabetes Mellitus
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases